The findings are a promising step for a disease with limited treatment options.

Study in people taking a biologic drug for autoimmune diseases shows association of patient support programs with reduced chance of starting opioid pain medicines or continuing on them.

A new potential biomarker raises concerns over the current standard for treating COVID-19 induced blood clots with high dose blood thinners.

Study finds NAD+ break down leads to multi organ scarring, providing now a previously undiscovered pathogenic role of the enzyme CD38 in disease scarring.

Osteopontin is discovered as the culprit behind these patients’ main cause of death. However, a repurposed immunosuppressive drug may combat the pro-inflammatory protein.

A new study reveals the virus triggers production of antibodies circulating through the blood, causing clots in people hospitalized with the disease.